Annexon Inc ANNX

$3.10 -0.31 (-9.09%)

Valuation

Market cap
591,368,000
Revenue TTM
$0
Net income TTM
$-206,690,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.35

Trading

Volume
4,457,100
Avg volume
3,540,810
Day's range
$3.07 – $3.37
Shares out
190,764,000
Stochastic %K
2%
Beta
1.43
Analysts
Moderate Buy
Price target
$17.00

Price

Company profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial fo...

Show more

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 822 5500
Website
https://www.annexonbio.com
Address
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States

Latest news

Stocktwits

Lightening_strikes Nov 21, 8:28 PM
$ANNX interesting! https://www.clinaptisresearch.com/company/annx
0 replies
Sly15 Nov 21, 12:51 PM
$ANNX I wish I had more money to buy down here
0 replies
Lightening_strikes Nov 21, 12:29 PM
$ANNX Director insider buys And readout imminent Ok!
1 replies
ignitionbio Nov 20, 11:32 PM
$SLS $ANNX $IBRX $AXTI $LXRX down across the board today and not concerned about any of these beauties!
1 replies
Lightening_strikes Nov 20, 8:22 PM
$ANNX this has been a slow torturous death
0 replies
Lightening_strikes Nov 20, 7:47 PM
$ANNX do they know dmc recommendation?
1 replies
Lightening_strikes Nov 20, 6:59 PM
$ANNX time to fire the ceo
0 replies
makingdoughfromoptions Nov 20, 6:00 PM
$ANNX Let's see, with a 90% chance of EMA approval for GBS as we are past clock stop 2 and fir 10/10 in Forward positively responded then the shorts and general flight to safety has beat the crap out of share price. That said, I have confidence minimally one drug will be approved. And you will kick yourself for not buying more at three bucks. If GA reads over 40% RRR then 3X minimally.
0 replies